CVS Health / Aetna

Health insurance claim denials are not random bureaucratic friction — they are business decisions with life-and-death consequences. The Aetna record documents that pattern across three decades. In 1999, a California jury awarded $116 million in punitive damages to the family of a man whose Aetna subsidiary had delayed approval of a recommended treatment for stomach cancer. The patient died. The case settled on appeal for $120.5 million in 2001. In 2003, Aetna reached a $470 million settlement with approximately 700,000 physicians and medical societies who alleged that Aetna had "systematically reduced payments to physicians and overriding treatment decisions" — embedding financial incentives into the medical authorization process in ways that denied patients care their doctors had ordered. In 2007, New Jersey fined Aetna $9.5 million for refusing to cover out-of-network emergency treatment when patients had no meaningful choice of provider. The 2018 revelation is the one that makes the rest legible. In a deposition in a California lawsuit brought by an HIV patient whose Aetna coverage had been revoked, the company's medical director Dr. Jay Ken Iinuma testified that he never reviewed any patient medical records before making coverage denial decisions. He relied on nurse reviewers' summaries only. California's Department of Insurance launched an investigation. The case settled in 2019; the California probe continued separately. The deposition is part of the public record. Aetna's business model, from 1999 through 2018, is documented. The mechanism is documented. No executive was criminally charged.

• —1999: California jury awarded $116M punitive damages for delayed stomach cancer treatment — patient died awaiting approval. Settled 2001 for $120.5M.
• —2001: Maryland fined Aetna $850K — largest of $1.4M total — for failing to comply with claims payment practices.
• —2001: Texas fined Aetna $1.15M for delayed physician and hospital payments.
• —2002: New York fined Aetna and UnitedHealthcare $2.5M jointly for mishandled claims, improper treatment denials.
• —2003: $470M settlement with 700,000 physicians — allegation: 'systematically reducing payments and overriding treatment decisions.'
• —2007: New Jersey fined Aetna $9.5M for refusing out-of-network emergency coverage.
• —2018: Medical director Dr. Jay Ken Iinuma testified he 'never reviewed any patients' medical records' when deciding claim approvals or denials.
• —California Department of Insurance investigation opened 2018; case settled 2019; state probe continued.
• —2021: Class action filed alleging Aetna treats mental health as less important than physical health.
• —No executive was criminally charged in connection with any denial practice.

The opioid epidemic killed more than 500,000 Americans between 1999 and 2019. The federal government's effort to assign legal responsibility reached pharmacy chains in 2021 — the first time pharmacies had defended themselves at opioid trial. The DEA's 2010–2011 investigation of CVS pharmacies in Sanford, Florida documented what the agency called striking dispensing volumes. A single CVS location was dispensing approximately 1.8 million oxycodone pills per month. DEA investigators noted that approximately every third car coming through the pharmacy's drive-thru lane had a prescription for oxycodone or hydrocodone. Pill mills — doctors writing prescriptions for anyone who paid cash — were directing their patients to specific CVS locations. CVS did not stop taking the prescriptions. In July 2020, Kentucky's attorney general filed suit alleging that CVS's business practices aided and advanced the opioid epidemic in Kentucky. In November 2021, a federal jury in Cleveland found CVS (alongside Walgreens and Walmart) had "substantially contributed" to the opioid epidemic in Lake County and Trumbull County, Ohio. It was the first trial in which pharmacy chains defended themselves in opioid litigation. The defense position — that pharmacists had only filled prescriptions written by licensed doctors — did not persuade the jury. In August 2022, Judge Dan Polster ordered CVS, Walgreens, and Walmart to pay $650.5 million in combined damages for the opioid harm in those two Ohio counties. The counties had sought $3.3 billion. Massachusetts had separately extracted a $795,000 settlement from CVS in 2016 for failing to check prescription monitoring databases before dispensing opioids and controlled substances. Kentucky's lawsuit was pending as of 2025. Zero CVS executives were criminally charged.

• —2010–2011: DEA investigation of Sanford, FL CVS location. Documented 1.8M oxycodone pills per month. DEA: 'approximately every third car that came through the drive-thru lane had prescriptions for oxycodone or hydrocodone.'
• —September 2016: Massachusetts settled with CVS for $795,000 for failure to consult Prescription Monitoring Program before dispensing opioids.
• —July 2020: Kentucky attorney general filed suit alleging CVS business practices advanced the opioid epidemic.
• —November 2021: Federal jury in Cleveland found CVS liable for 'substantially contributing' to the opioid epidemic in Lake County and Trumbull County, Ohio — first pharmacy opioid trial verdict.
• —August 2022: $650.5M in damages ordered against CVS, Walgreens, and Walmart combined for two Ohio counties.
• —Original damages sought by Ohio counties: $3.3 billion.
• —Zero CVS executives criminally charged in connection with opioid dispensing practices.

Pharmacy benefit managers — PBMs — sit between drug manufacturers and patients, theoretically negotiating lower prices. In practice, the FTC documented them as extractive intermediaries who profit from the opacity of drug pricing at every stage. CVS Caremark is the pharmacy benefit management arm of CVS Health, administering drug benefits for approximately 100 million plan members. It is the second-largest PBM in the United States (after OptumRx, a UnitedHealth subsidiary). The three largest PBMs — CVS Caremark, OptumRx, and Express Scripts — collectively process approximately 80% of U.S. prescriptions. The documented abuses follow two core patterns. Spread pricing: Caremark negotiates drug prices from manufacturers, then resells to health plans at a higher public list price — pocketing the difference. Clawbacks: in approximately 25% of transactions, the patient's insurance copayment calculated on the list price exceeds the full cash price of the drug. The PBM claws back the excess from the pharmacy. The patient paid more than the drug cost; the PBM kept the excess; the patient received no refund. In 2005, CVS Caremark (then Caremark Rx) paid $137.5 million to settle federal whistleblower lawsuits alleging improper dealings with pharmaceutical manufacturers — keeping discounts that should have been passed to member benefit plans. In 2008, CVS paid $38.5 million to 28 state attorneys general for deceptive PBM practices including unauthorized drug switching. In 2011, CVS paid $20 million to three states for keeping manufacturer discounts and steering members toward more expensive drugs. In September 2024, the FTC sued CVS Caremark alongside the other two major PBMs — the most significant regulatory action against the PBM industry in its history. In March 2026, CVS reached a proposed settlement with the FTC on insulin pricing, agreeing to alter business practices and adopt more transparent policies without admitting wrongdoing or paying financial penalties. The mechanism the FTC documented is legal under current law. The FTC's suit argues it is anticompetitive. Congress has conducted multiple investigations. No CVS executive was criminally charged.

• —2005: Caremark Rx paid $137.5M to settle federal whistleblower lawsuits — alleged improper dealings with drug manufacturers; kept discounts instead of passing to benefit plans.
• —2008: CVS paid $38.5M to 28 state attorneys general for deceptive PBM practices including drug switching.
• —2011: CVS paid $20M to three states — kept manufacturer discounts; provided members more expensive drugs when cheaper alternatives existed.
• —Spread pricing: Caremark resells drugs at list price higher than negotiated net price; pockets the margin.
• —Clawbacks: ~25% of transactions — patient's copay on list price exceeds cash price of drug; PBM keeps the difference; patient receives no refund.
• —September 2024: FTC sued CVS Caremark alongside Express Scripts and OptumRx — 'drug pricing practices.'
• —March 2026: CVS proposed FTC settlement on insulin pricing — altered business practices; no financial penalty; no admission of wrongdoing.
• —As of 2026: Three largest PBMs (Caremark, OptumRx, Express Scripts) process ~80% of US prescriptions. All three are vertically integrated into insurance or pharmacy chains.
• —Zero CVS executives criminally charged in connection with PBM pricing practices.